Table 1.
Patient characteristics.
| Patients, N | 35 |
| Female, N (%) | 10 (28.6) |
| Age at diagnosis, median (range) | 61 (40–80) |
| ECOG PS, N (%) | |
| After diagnostic surgery | |
| 0 | 20 (57.1) |
| 1 | 13 (37.1) |
| 2 | 2 (5.7) |
| PS, N (%) | |
| After relapse surgery | |
| 0 | 11 (31.4) |
| 1 | 12 (34.3) |
| 2 | 12 (34.3) |
| MGMT‐non‐methylated, N (%) | 28 (80) |
| IDH‐WT, N (%) | 35 (100) |
| Treatment, N (%) | |
| STUPP a | 28 (80) |
| IT (trial) b | 4 (11.4) |
| Other c | 3 (8.6) |
| Sample preservation, N (%) | |
| Diagnostic surgery | |
| RNAlater | 25 (71.4) |
| FFPE | 8 (22.9) |
| Snap‐frozen | 2 (5.7) |
| Sample preservation, N (%) | |
| Relapse surgery | |
| RNAlater | 19 (54.3) |
| FFPE | 16 (45.7) |
| Snap‐frozen | 0 (0) |
| PFS, months (median) | |
| Diagnostic surgery | 7.5 |
| Relapse surgery | 5.5 |
| OS, months (median) | |
| Diagnostic surgery | 16.2 |
| Relapse surgery | 8.9 |
a
RT with 60 Gy/30F concurrent with TMZ followed by adjuvant TMZ.
b
RT/TMZ plus a PD1i in a trial. One patient received RT/TMZ plus PD1i or placebo.
c
30 Gy/10F or 60 Gy/30F.